<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074086</url>
  </required_header>
  <id_info>
    <org_study_id>RAD 001</org_study_id>
    <nct_id>NCT01074086</nct_id>
  </id_info>
  <brief_title>Phase I Study in RAD 001 Patients With Relapse AML</brief_title>
  <official_title>Multicentric Study of GOELAMS Phase I Evaluation of RAD001 in Association With Aracytine and Daunorubicine in AML Treatment in Patients Less Than 65 Years in Relapse More Than One Year After First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I clinical study in evaluation of RAD 001 with aracytine and daunorubicine in AML
      treatment of patients older less than 65 years in relapse
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to determinate the maximal tolerate dose and evaluate
      the toxicity of RAD 001 in patients older less than 65 years in AML relapse in association
      with a conventional chemotherapy 5Aracytine and Daunorubicine) in an dose escalated phase I
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximal dose tolerated</measure>
    <time_frame>40 days</time_frame>
    <description>5 steps of RAD 001 doses from 10mg to 50 mg : 3 patienst for each step</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological study</measure>
    <time_frame>Day 1 and day 7</time_frame>
    <description>biological study of PI3K/AKT an mTORC1 activation in blast cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological study</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>concentration mesures of RAD 001 in total blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>RAD 001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD 001 in day 1 and day 7 from 10 mg to 50 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD 001</intervention_name>
    <description>RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg</description>
    <arm_group_label>RAD 001</arm_group_label>
    <other_name>everolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients from 18 to 65 years old

          -  AML in relapse more than 1 year after CR

          -  inform consent signed

        Exclusion Criteria:

          -  age more than 65

          -  cardiac insufficiency

          -  renal insufficiency

          -  hepatic disease

          -  other type of AML

          -  blastic MCL

          -  HIV positive serology

          -  other malignancy

          -  pulmonary infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie PARK, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Didier BOUSCArY, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sophie Park</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <last_update_submitted>December 21, 2012</last_update_submitted>
  <last_update_submitted_qc>December 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RAD 001 in relapsed AML</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

